SURF News and Press, Surface Oncology Inc. From 03/09/23

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into th...

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a ...

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a ...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that its licensee, Surface Oncology (NAS...

SRF114 is designed to preferentially deplete CCR8 + Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. ...

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of two posters at the 2022 Society for Immunother...

Surface Oncology ( NASDAQ: SURF ) is laying off about 20% of its employees and pausing developing of SRF617, a phase 2 candidate targeting CD39 for solid tumors. The company is focusing resources on SRF388 and SRF144. The former is in phase 2 for hepatocellular carcino...

– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year – – Company focusing resources on advancement of SRF388 and SRF114, extending cash r...

– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine – – Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting the cytokine’s signaling activity – ...